Loading data for GSK — first visit, this takes a few seconds.

알림

GSK (GSK)

NYSE: GSK · 실시간 가격 · USD

50.28

+0.76 (1.53%)

종가 기준: Aug 17, 2026, 8:00 PM

1.53% (1D)

데이터 없음

매수호가	50.25
시가총액	100.7B
매출 (ttm)	33.2B
순이익 (ttm)	4.82B
베타	0.29
EPS (ttm)	3.23
P/E (ttm)	15.57
선행 P/E	9.79
P/B (ttm)	4.25
P/S (ttm)	3.03
Earnings Date	Oct 28, 2026

매도호가	50.35
거래량	2,566,979
평균 거래량 (20일)	3,974,263
시가	49.93
전일 종가	49.52
일중 범위	49.88 - 50.36
52주 범위	38.63 - 61.70
애널리스트	n/a
목표주가	n/a
배당	$1.82 (3.67%)
배당락일	2026년 8월 14일

GSK 소개

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respirator...

[더 보기]

산업 Drug Manufacturers - General

섹터 Healthcare

IPO 일자 Mar 28, 1980

직원 수 66,841

상장 거래소 NYSE

티커 GSK

웹사이트 https://www.gsk.com

전체 기업 정보

재무 실적

2025년 GSK의 매출은 32.67B로, 전년 31.38B 대비 4.11% 증가했습니다. 순이익은 5.72B로, 121.98% 증가했습니다.

재무제표

어닝 서프라이즈

GSK가 Jul 28, 2026에 분기 실적을 발표했습니다:

매출 $8.41B 예상치 하회 $0, 및 5.30% 전년 대비 성장.

EPS 1.34 예상치 상회 0.09, 및 8.06% 전년 대비 성장.

다음 실적 발표

GSK의 실적 발표 예정일은 Oct 28, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · MT Newswires

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

European equities traded in the US as American depositary receipts started the week tracking modestl

5일 전 · Insider Monkey

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover rea...

6일 전 · 24/7 Wall St.

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer....

1주 전 · Bloomberg

Trump Plans to Sign Order on Splitting Up Combined Measles Shot

(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, accordin...

2주 전 · Zacks

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

2 페이지 중 1